DEUTSCHE-POST-DHL-GROUP
Deutsche Post DHL Group (Symbol: DPW), the world’s leading logistics company, has today released preliminary results for the third quarter of 2021. The Group’s EBIT reached around EUR 1.765 billion in the third quarter 2021 (Q3 2020: EUR 1.377 billion), bringing the EBIT of the first nine months of 2021 to around EUR 5.760 billion. This includes a one-off effect of EUR -179 million for the second Covid-19 bonus (Q3 2020: EUR -163 million), which will be paid in the fourth quarter. Against the backdrop of the excellent business development, the Group will revise upward its outlook for EBIT and free cash flow for FY 2021. In addition, the mid-term guidance for FY 2023 will be increased on November 4, 2021.
“In the first nine months of the current year, we have already exceeded previous year’s full-year result. Global trade accelerated significantly compared to the previous year. At the same time, shipment volumes in e-commerce remained high. Therefore we are optimistic for the oncoming peak season“, said Frank Appel, CEO of Deutsche Post DHL Group. “We are now intensively preparing ourselves for potential record breaking shipment volumes in the coming weeks and have deliberately built up capacity in the third quarter, in order to be able to offer our customers continued high quality service.”
DHL divisions achieved a significant jump in earnings
The positive development of the group's businesses seen in the first half of the year has continued well through the third quarter 2021. All DHL divisions significantly exceeded the previous year's results. Volume trends in the past quarter confirm base assumptions with continued well supported B2B recovery and B2C volumes staying at high previous year levels across all major networks. At the same time the tight capacity situation both in Ocean and Air Freight markets continued.
Express: EBIT in the Express division reached around EUR 970 million in the third quarter 2021 compared to EUR 753 million in the previous year’s quarter.
Global Forwarding, Freight: EBIT in Global Forwarding, Freight stood at around EUR 370 million in the third quarter 2021, also clearly ahead of previous year’s result of EUR 155 million.
Supply Chain: EBIT at Supply Chain came in at around EUR 140 million in the third quarter 2021, significantly above last year's third quarter result which stood at EUR 112 million.
eCommerce Solutions: eCommerce Solutions recorded EBIT of around EUR 90 million in the third quarter 2021, significantly above last year’s third quarter result which stood at EUR 76 million.
Post & Parcel Germany: EBIT in Post & Parcel Germany in the third quarter 2021 was around EUR 300 million (Q3 2020: EUR 320 million).
The continued positive business development is underpinned by a continued equally strong development of cash flow; free cash flow in the third quarter 2021 amounted to more than EUR 1.0 billion (Q3 2020: EUR 1.264 billion). For the first nine months of 2021 free cash flow stands at more than EUR 3.1 billion and significantly exceeds the previous year result (9M 2020: EUR 1.460 billion).
Earnings and FCF outlook will be revised upwards based on dynamic business performance
In light of the continued positive earnings momentum also in the third quarter 2021, management will raise guidance for FY 2021 Group EBIT and FCF, driven by the strong development in the DHL divisions. Also, the mid-term guidance for FY 2023 will be subject to upward revision.
The comprehensive disclosure for third quarter 2021 will be published as planned on November 4, 2021.
– End –
Deutsche Post DHL Group is the world’s leading logistics company. The Group connects people and markets and is an enabler of global trade. It aspires to be the first choice for customers, employees and investors worldwide. The Group contributes to the world through responsible business practice, corporate citizenship and environmental activities. By the year 2050, Deutsche Post DHL Group aims to achieve zero emissions logistics.
Deutsche Post DHL Group is home to two strong brands: Deutsche Post is Europe’s leading postal service. DHL offers a comprehensive range of international express, freight transport, and supply chain management services as well as e-commerce logistics solutions. Deutsche Post DHL Group employs approximately 570,000 people in over 220 countries and territories worldwide. The Group generated revenues of more than 66 billion Euros in 2020.
THE logistics company for the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005668/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom